Roche announces new data reinforcing the long-term benefit of Venclexta/Venclyxto-based combination for people with relapsed or refractory chronic lymphocytic leukaemia

             Basel, 5 December 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from the pivotal phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta ®/Venclyxto® (venetoclax)-based combinations in certain people with chronic lymphocytic leukaemia (CLL) and provide more evidence on the potential value of minimal residual disease (MRD). Data were presented at the all-virtual 62nd American Society of Hematology (ASH) Annual Meeting and Exposition on Saturday 5 December 2020.“These results reinforce the long-term value of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based combinations in CLL, potentially offering patients a significant period of time without treatment following initial therapy,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Offic er and Head of Global Product Development. “These data also reflect our ongoing commitment to accelerating clinical advancements for patients by exploring the novel endpoint minimal residual disease as a potential predictor of patient outcomes.” Five-year data from the pivotal phase III MURANO trial continue to show sustained investigator-assessed progression-free survival (PFS) with Venclexta/Venclyxto plus MabThera®/Rituxan®(rituximab). Data, presented in an oral session, showed:
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news

Related Links:

Tugba Cetintepe, Fusun Gedız Kobak, Sadi BenerIndian Journal of Cancer 2021 58(3):428-430 A 67-year-old woman was diagnosed with Chronic Lymphocytic Leukemia (CLL) and chemotherapy was started. Due to epileptic seizure and left hemiplegia that developed on the twenty first day of the treatment, cranial magnetic resonance imaging was performed and a markedly increased mass of a diameter of 5 cm in the right frontal lobe was seen. Diffuse large B-cell non-Hodgkin lymphoma was concluded at diagnostic brain biopsy. Repeated bone marrow biopsy implemented simultaneously, was reported as CLL. Based on the diagnosis of isol...
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
In conclusion, patients with CLL/lymphomas have low humoral response following COVID-19 vaccination, underlining the need for timely vaccination ideally during a treatment-free period and for continuous vigilance on infection control measures.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Leuk Res. 2021 Aug 4;111:106684. doi: 10.1016/j.leukres.2021.106684. Online ahead of print.ABSTRACTThe in vivo rituximab effects in B cell malignancies are only partially understood. Here we analyzed in a large chronic lymphocytic leukemia (CLL) cohort (n = 80) the inter-patient variability in CLL cell count reduction within the first 24 h of rituximab administration in vivo, and a phenomenon of blood repopulation by malignant cells after anti-CD20 antibody therapy. Larger CLL cell elimination after rituximab infusion was associated with lower pre-therapy CLL cell counts, higher CD20 levels, and the non-exhausted capacity ...
Source: Cell Research - Category: Cytology Authors: Source Type: research
alapai Mannucci Sgambato Efremov Laurenti Membrane-bound CD200 is overexpressed in chronic lymphocytic leukemia (CLL), and there is some evidence that its soluble ectodomain (sCD200) could also be involved in the pathophysiology and the disease. However, very little is known about sCD200’s prognostic significance. sCD200 was tested at diagnosis in 272 patients with CLL and in 78 age- and sex-matched healthy subjects using a specific human CD200 (OX-2 membrane glycoprotein) ELISA kit. A significantly higher concentration of sCD200 was found in CLL patients compared to controls. In our cohort, sCD200 wa...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Cancer J. 2021 Jul-Aug 01;27(4):275-285. doi: 10.1097/PPO.0000000000000530.ABSTRACTOver the last 2 decades, treatment of chronic lymphocytic leukemia (CLL) therapy has drastically changed, resulting in greatly improved survival and treatment tolerance with current targeted therapies. First, the transition from chemotherapy (alkylating agents, nucleoside analogs) to chemoimmunotherapy with the addition of anti-CD20 antibodies resulted in deeper and more complete remissions, with an improvement in progression-free and overall survival. Over the last few years, chemoimmunotherapy has gradually been replaced by new targeted ag...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
Cancer J. 2021 Jul-Aug 01;27(4):259-265. doi: 10.1097/PPO.0000000000000538.ABSTRACTDuring the past 10 years, relevant advances have been made in the understanding of the pathogenesis of chronic lymphocytic leukemia via the integrated analysis of its genome and related epigenome, and transcriptome. These analyses also had an impact on our understanding of the initiation, as well as of the evolution of chronic lymphocytic leukemia, including resistance to chemotherapy and sensitivity and resistance to novel targeted therapies. This chapter will review the current state of the art in this field, with emphasis on the genetic h...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
Cancer J. 2021 Jul-Aug 01;27(4):275-285. doi: 10.1097/PPO.0000000000000530.ABSTRACTOver the last 2 decades, treatment of chronic lymphocytic leukemia (CLL) therapy has drastically changed, resulting in greatly improved survival and treatment tolerance with current targeted therapies. First, the transition from chemotherapy (alkylating agents, nucleoside analogs) to chemoimmunotherapy with the addition of anti-CD20 antibodies resulted in deeper and more complete remissions, with an improvement in progression-free and overall survival. Over the last few years, chemoimmunotherapy has gradually been replaced by new targeted ag...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
Cancer J. 2021 Jul-Aug 01;27(4):259-265. doi: 10.1097/PPO.0000000000000538.ABSTRACTDuring the past 10 years, relevant advances have been made in the understanding of the pathogenesis of chronic lymphocytic leukemia via the integrated analysis of its genome and related epigenome, and transcriptome. These analyses also had an impact on our understanding of the initiation, as well as of the evolution of chronic lymphocytic leukemia, including resistance to chemotherapy and sensitivity and resistance to novel targeted therapies. This chapter will review the current state of the art in this field, with emphasis on the genetic h...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
Cancer J. 2021 Jul-Aug 01;27(4):275-285. doi: 10.1097/PPO.0000000000000530.ABSTRACTOver the last 2 decades, treatment of chronic lymphocytic leukemia (CLL) therapy has drastically changed, resulting in greatly improved survival and treatment tolerance with current targeted therapies. First, the transition from chemotherapy (alkylating agents, nucleoside analogs) to chemoimmunotherapy with the addition of anti-CD20 antibodies resulted in deeper and more complete remissions, with an improvement in progression-free and overall survival. Over the last few years, chemoimmunotherapy has gradually been replaced by new targeted ag...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
Cancer J. 2021 Jul-Aug 01;27(4):259-265. doi: 10.1097/PPO.0000000000000538.ABSTRACTDuring the past 10 years, relevant advances have been made in the understanding of the pathogenesis of chronic lymphocytic leukemia via the integrated analysis of its genome and related epigenome, and transcriptome. These analyses also had an impact on our understanding of the initiation, as well as of the evolution of chronic lymphocytic leukemia, including resistance to chemotherapy and sensitivity and resistance to novel targeted therapies. This chapter will review the current state of the art in this field, with emphasis on the genetic h...
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research
More News: Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Hematology | Leukemia | Pharmaceuticals | Rituxan | Study